All News

PSA%20026.jpg

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

d Jack Cush, MD

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

Read Article
SPA.spectrum.jpg

SPARTAN ACR20 Recommendations on Spondyloarthritis

d Jack Cush, MD

SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.

Read Article
moneyglobe.jpg

US Differs from Worldwide Drug Reimbursements

d Jack Cush, MD

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Read Article
virtual upcoming laptop

Are Rheums Attending ACR 2020?

d Jack Cush, MD

ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th. 

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

d Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
pssfing.jpg

Abatacept in Early Systemic Sclerosis (ASSET study)

d Jack Cush, MD

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Read Article

Systematic review of the literatures (19 studies, 241 138 participants) shows ibuprofen vs acetaminophen for fever or pain in children <2 years was associated with equivalent safety and improved temperature and pain within the first 24 hours https://t.co/4y5dww22Gw

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 55 SpA patients with axial disease. 31% had high risk of falls (by survey) and 25% recalled having at least one fall in the last years. Risk higher w/ activity and adv disease. Pts w/ falls had lower quality of life. https://t.co/yu6mP6sxth

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis https://t.co/I2dzetdgBw

Links:

Dr. John Cush RheumNow ( View Tweet)

Lowest Specialty Salaries in 2020 Preventive med: $234K Pediatrics: $243K Medical genetics: $252K Endocrine: $259K Family med: $261K Geriatrics: $272K Infectious dz: $277K Internal med: $280K Rheumatology: $289K Occupational med: $293K Rheum! we are #9 https://t.co/zEs8WxVgG9

Links:

Dr. John Cush RheumNow ( View Tweet)

Exciting to hear about 5 trials for #GCA 1. ABAGART (#Abatacept) 2. METOGIA (#tocilizumab vs MTX) 3. SELECT (#upadacitinib) 4. MAVRILIMUMAB (#gmcsf i) 5. TiTIAN (#secukinumab) ⁦@VasculitisFound⁩ #vasculitis #vcrc https://t.co/DVvG5Ekfu9
KenWarringtonMD MdWarrington ( View Tweet)
Did you see the results of our "Are Rheums Attending ACR 2020?" Survey. 41% will attend live 23% will learn off hours 2/3 are registered for ACR 20% just won't go 37% are taking time off to attend See ou recs on how to learn based on where you fit above https://t.co/K4qHSJ07P2

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

Dr. John Cush RheumNow ( View Tweet)

This is the best blog I've ever written. https://t.co/u2kHUD4sSw

Links:

Dr. John Cush RheumNow ( View Tweet)

Wilson’s dz- autosomal recessive w/ incr copper deposition in brain, liver & joints (<50%) w/ premature OA in wrist, MCPs, knees & spine. Dx by LOW serum ceruloplasmin , HIGH urinary copper, hepatic copper levels, or mutations in ATP7B gene https://t.co/CoEpcjRnHt

Links:

Dr. John Cush RheumNow ( View Tweet)

QD104 - You Are So Not Disabled QD Clinic - Lessons from the clinic Grappling with Disability Letter Requests Features Dr. Jack Cush https://t.co/Vg5i9rHyKN

Links:

Dr. John Cush RheumNow ( View Tweet)

Metaanalysis of 7 cohort studies, 34 029 biologic & 135370 biologic-naive Pts (RA, PsO, IBD) looked at risk of melanoma (vs conventional Rx). Found no statistically significant increase risk for melanoma w/ biologics (eg RA RR 1.2; 95% CI, 0.83-1.74) https://t.co/rnZwzqE8m2

Links:

Dr. John Cush RheumNow ( View Tweet)

Intnl psoriasis registry reports Less hospitalization in PSO on biologics (16% vs 33%); higher HR 2.8 on non-biologics. 374 Psoriasis pts w/ COVID-19, 71% on biologic, 18% non-biologic & 10% no systemic Rx. 93% fully recovered. 21% hospitalized, 2% died. https://t.co/xLaPrkfDCf

Links:

Dr. John Cush RheumNow ( View Tweet)

25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids https://t.co/wln0FrI0Iz

Links:

Dr. John Cush RheumNow ( View Tweet)

Population study from NY of 168,234 hip replacements and 308,477 knee TKAs showed that total joint arthroplasty was associated with a 34-44% decrease risk of falls (THA HR 0.56; TKA HR 0.66). Risk of falls incr w/ age- 70-79 yrs (HR4.3), 80+ yrs (HR 5.5) https://t.co/KeejsfGEjn

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×